Imbria Pharmaceuticals

Focus: Imbria Pharmaceuticals is a neurology-focused biotech developing partial fatty acid oxidation (pFOX) inhibitors as a novel therapeutic mechanism. The company is at Series B stage, indicating early-stage clinical development and pre-commercial scale.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES B

Open Jobs

About Imbria Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Imbria Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

IMB-1018972

Refractory Angina

Phase 2

Clinical Trials (1)

NCT04306237A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina

Phase 2

Help build intelligence for Imbria Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to build careers at ground level in a company developing a novel, differentiated mechanism (pFOX inhibition) in neurology, a high-value therapeutic area
Series B stage means meaningful equity upside potential if pipeline programs advance and company achieves clinical/commercial milestones
Boston location provides access to premier pharma/biotech talent networks and ecosystem partnerships

Watch Out For

Pre-revenue, pre-commercial status means no product revenue to support operations long-term; dependent on future funding rounds and clinical success
No active job openings reported and limited hiring data suggests company may be in focused development phase rather than growth mode
No disclosed clinical trial data (0 programs across Phase 1/2/3) makes it difficult to assess pipeline credibility or near-term value creation catalysts

Generated by Claude from Imbria Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Ninerafaxstat 200mg MR

Non-obstructive Hypertrophic Cardiomyopathy

Phase 2

Clinical Trials (1)

NCT07023614A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Phase 2

IMB-1018972

Non-obstructive Hypertrophic Cardiomyopathy

Phase 2

Clinical Trials (1)

NCT04826185A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial

Phase 2

IMB-1018972

Type 2 Diabetes

Phase 2

Clinical Trials (1)

NCT04826159IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)

Phase 2

IMB-1018972

Ischemia

Phase 2

Clinical Trials (1)

NCT04826172Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia)

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

Top TAs: Cardiovascular, Metabolic Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Cardiovascular

4 pipeline

Metabolic Diseases

1 pipeline

Marketed

Pipeline